Targeting the UPS as therapy in multiple myeloma

Area of Science:

• Cellular Biology
• Biochemistry
• Pharmacology

Background:

• Cellular homeostasis relies on regulated protein synthesis and degradation via the ubiquitin proteasome system.
• The 26S proteasome degrades unwanted proteins; its inhibition causes protein aggregation and cell death, forming the basis for cancer therapeutics.
• Bortezomib, a proteasome inhibitor, is FDA-approved for multiple myeloma but faces challenges with toxicity and drug resistance.

Purpose of the Study:

• To review the role of the ubiquitin proteasome system in cellular function and disease.
• To discuss the development and clinical application of proteasome inhibitors in multiple myeloma treatment.
• To highlight strategies for overcoming bortezomib resistance and toxicity, including combination therapies and novel inhibitors.

Main Methods:

• Literature review of studies on the ubiquitin proteasome system and proteasome inhibitors.
• Analysis of preclinical data on combination therapies and novel proteasome inhibitors.
• Examination of clinical trial outcomes for bortezomib and emerging treatments in multiple myeloma.

Main Results:

• Proteasome inhibition is a validated strategy for treating multiple myeloma.
• Bortezomib has demonstrated clinical efficacy but is limited by toxicity and resistance.
• Combination therapies and novel proteasome inhibitors show potential to improve treatment outcomes and manage resistance.

Conclusions:

• Targeting the ubiquitin proteasome system is a key therapeutic strategy in oncology, particularly for multiple myeloma.
• Overcoming bortezomib resistance and toxicity is achievable through combination therapies and the development of next-generation proteasome inhibitors.
• Ongoing research and clinical evaluation of novel agents aim to enhance patient outcomes in multiple myeloma.